Bristol Myers Squibb scored a development milestone for arlocabtagene autoleucel after results in a Phase 2 study met endpoints that analysts view as a “derisking event.” The QUINTESSENTIAL trial targeted relapsed and refractory multiple myeloma patients with quadruple-class exposure, positioning BMS to compete in a segment where durable response rates have been hard to achieve.